US Patent Issued to Brandeis University on April 15 for "Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis (ALS) by UPF2" (New York, Ohio, Massachusetts Inventors)

ALEXANDRIA, Va., June 5 -- United States Patent no. 12,275,764, issued on April 15, was assigned to Brandeis University (Waltham, Mass.).

"Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis (ALS) by UPF2" was invented by Greg Petsko (New York), Dagmar Ringe (Cambridge, Mass.) and Shulin Ju (Beavercreek, Ohio).

According to the abstract* released by the U.S. Patent & Trademark Office: "Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described."

The patent was filed on April 15, 2022, under Application No. 17/72...